Literature DB >> 24257347

Evaluation of engraftment and immunological tolerance after reduced intensity conditioning in a rhesus hematopoietic stem cell gene therapy model.

N Uchida1, R P Weitzel1, M E Evans1, R Green1, A C Bonifacino2, A E Krouse2, M E Metzger2, M M Hsieh1, R E Donahue2, J F Tisdale1.   

Abstract

Reduced intensity conditioning (RIC) is desirable for hematopoietic stem cell (HSC) targeted gene therapy; however, RIC may be insufficient for efficient engraftment and inducing immunological tolerance to transgenes. We previously established long-term gene marking in our rhesus macaque autologous HSC transplantation model following 10 Gy total body irradiation (TBI). In this study, we evaluated RIC transplantation with 4 Gy TBI in two rhesus macaques that received equal parts of CD34(+) cells transduced with green fluorescent protein (GFP)-expressing lentiviral vector and empty vector not expressing transgenes. In both animals, equivalently low gene marking between GFP and empty vectors was observed 6 months post-transplantation, even with efficient transduction of CD34(+) cells in vitro. Autologous lymphocyte infusion with GFP marking resulted in an increase of gene marking in lymphocytes in a control animal with GFP tolerance, but not in the two RIC-transplanted animals. In vitro assays revealed strong cellular and humoral immune responses to GFP protein in the two RIC-transplanted animals, but this was not observed in controls. In summary, 4 Gy TBI is insufficient to permit engraftment of genetically modified HSCs and induce immunological tolerance to transgenes. Our findings should help in the design of conditioning regimens in gene therapy trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24257347      PMCID: PMC4699286          DOI: 10.1038/gt.2013.67

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  34 in total

1.  Induction of transgene-specific immunological tolerance in myeloablated nonhuman primates using lentivirally transduced CD34+ progenitor cells.

Authors:  Sam K P Kung; Dong-Sung An; Aylin Bonifacino; Mark E Metzger; Gene-Errol Ringpis; Si-Hua Mao; Irvin S Y Chen; Robert E Donahue
Journal:  Mol Ther       Date:  2003-12       Impact factor: 11.454

2.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Christof von Kalle; Manfred Schmidt; Françoise Le Deist; Nicolas Wulffraat; Elisabeth McIntyre; Isabelle Radford; Jean-Luc Villeval; Christopher C Fraser; Marina Cavazzana-Calvo; Alain Fischer
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

Review 3.  Pathogenesis and treatment of sickle cell disease.

Authors:  H F Bunn
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

4.  High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments.

Authors:  K E Pollok; H Hanenberg; T W Noblitt; W L Schroeder; I Kato; D Emanuel; D A Williams
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 5.  Non-myeloablative transplants for malignant disease.

Authors:  R F Storb; R Champlin; S R Riddell; M Murata; S Bryant; E H Warren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2001

6.  A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

Authors:  Steven G Deeks; Bridget Wagner; Peter A Anton; Ronald T Mitsuyasu; David T Scadden; Christine Huang; Catherine Macken; Douglas D Richman; Cindy Christopherson; Carl H June; Richard Lazar; David F Broad; Sayeh Jalali; Kristen M Hege
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

7.  Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system.

Authors:  Hideki Hanawa; Peiman Hematti; Keyvan Keyvanfar; Mark E Metzger; Allen Krouse; Robert E Donahue; Steve Kepes; John Gray; Cynthia E Dunbar; Derek A Persons; Arthur W Nienhuis
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

8.  Specific antibodies to hemoglobin A1 (anti-Glu) and hemoglobin S (anti-Val) in the guinea pig: immunologic and structural correlations.

Authors:  S Otieno; A Bloor; R Karol; M Reichlin; R W Noble
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

9.  Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability.

Authors:  J F Tisdale; Y Hanazono; S E Sellers; B A Agricola; M E Metzger; R E Donahue; C E Dunbar
Journal:  Blood       Date:  1998-08-15       Impact factor: 22.113

10.  CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes.

Authors:  Richard V Parry; Catherine A Rumbley; Luk H Vandenberghe; Carl H June; James L Riley
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

View more
  10 in total

1.  Discordance in lymphoid tissue recovery following stem cell transplantation in rhesus macaques: an in vivo imaging study.

Authors:  Robert E Donahue; Sharat Srinivasula; Naoya Uchida; Insook Kim; Alexis St Claire; Gorka Duralde; Paula DeGrange; Marisa St Claire; Richard C Reba; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Chang H Paik; H Clifford Lane; John F Tisdale; Michele Di Mascio
Journal:  Blood       Date:  2015-10-22       Impact factor: 22.113

2.  TRIM5α variations influence transduction efficiency with lentiviral vectors in both human and rhesus CD34(+) cells in vitro and in vivo.

Authors:  Molly E Evans; Chutima Kumkhaek; Matthew M Hsieh; Robert E Donahue; John F Tisdale; Naoya Uchida
Journal:  Mol Ther       Date:  2013-10-23       Impact factor: 11.454

3.  Busulfan Combined with Immunosuppression Allows Efficient Engraftment of Gene-Modified Cells in a Rhesus Macaque Model.

Authors:  Naoya Uchida; Tina Nassehi; Claire M Drysdale; Jackson Gamer; Morgan Yapundich; Aylin C Bonifacino; Allen E Krouse; Nathaniel Linde; Matthew M Hsieh; Robert E Donahue; Cynthia E Dunbar; Leslie S Kean; John F Tisdale
Journal:  Mol Ther       Date:  2019-06-05       Impact factor: 11.454

4.  Modeling promising nonmyeloablative conditioning regimens in nonhuman primates.

Authors:  Devikha Chandrasekaran; Betty Nakamoto; Korashon L Watts; Hans-Peter Kiem; Thalia Papayannopoulou
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

Review 5.  Immunoresponse to Gene-Modified Hematopoietic Stem Cells.

Authors:  Claire M Drysdale; John F Tisdale; Naoya Uchida
Journal:  Mol Ther Methods Clin Dev       Date:  2019-10-31       Impact factor: 6.698

6.  Preclinical evaluation for engraftment of CD34+ cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models.

Authors:  Naoya Uchida; Linhong Li; Tina Nassehi; Claire M Drysdale; Morgan Yapundich; Jackson Gamer; Juan J Haro-Mora; Selami Demirci; Alexis Leonard; Aylin C Bonifacino; Allen E Krouse; N Seth Linde; Cornell Allen; Madhusudan V Peshwa; Suk See De Ravin; Robert E Donahue; Harry L Malech; John F Tisdale
Journal:  Cell Rep Med       Date:  2021-04-20

Review 7.  Immunological barriers to haematopoietic stem cell gene therapy.

Authors:  Carsten T Charlesworth; Ian Hsu; Adam C Wilkinson; Hiromitsu Nakauchi
Journal:  Nat Rev Immunol       Date:  2022-03-17       Impact factor: 108.555

8.  Nestin-GFP transgene labels immunoprivileged bone marrow mesenchymal stem cells in the model of ectopic foci formation.

Authors:  Dmitriy Karpenko; Nikolay Kapranov; Aleksei Bigildeev
Journal:  Front Cell Dev Biol       Date:  2022-09-05

9.  Total body irradiation must be delivered at high dose for efficient engraftment and tolerance in a rhesus stem cell gene therapy model.

Authors:  Naoya Uchida; R Patrick Weitzel; Anna Shvygin; Luke P Skala; Lydia Raines; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Robert E Donahue; John F Tisdale
Journal:  Mol Ther Methods Clin Dev       Date:  2016-09-14       Impact factor: 6.698

Review 10.  Genetic Strategies for HIV Treatment and Prevention.

Authors:  Alexander Falkenhagen; Sadhna Joshi
Journal:  Mol Ther Nucleic Acids       Date:  2018-09-29       Impact factor: 8.886

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.